RenehaVis ((1×15.4mg/0.7ml))

• •  

    What is RenehaVis?

    RenehaVis is a sodium hyaluronate product, comprising a dual-chambered prefilled syringe that enables administration of both high and low molecular weight hyaluronate in a single intra-articular injection. Using high and low molecular weight sodium hyaluronate improves both cushioning and elasticity, enabling improvement in movement and pain relief at rest and during activity.

    A product designed to relieve pain and stiffness of the knee joint in patients with degenerative changes to the synovial joint, including osteoarthritis. RenehaVis contains 2 different Hyaluronic Acids with 2 different concentrations in 1 syringe, either 15.4mg/0.7ml or 7.0mg/0.7ml.

    A product designed and approved to relieve pain and stiffness of the knee joint in patients with degenerative changes to the synovial joint, including osteoarthritis. RenehaVis contains 2 different Hyaluronic Acids with 2 different concentrations in 1 syringe.

    RenehaVis contains 2 different Hyaluronic Acids with 2 different concentrations in 1 syringe.

  What is RenehaVis?RenehaVis is a sodium hyaluronate product, comprising a dual-chambered prefilled syringe that enables administration of both high and low molecular weight hyaluronate in a single intra-articular injection. Using high and low molecular weight sodium hyaluronate improves both cushioning and elasticity, enabling improvement in movement and pain relief at rest and during activity.

RenehaVisTM is two clear solutions of sterile sodium hyaluronate
in a phosphate buffered saline contained in a two chamber prefilled syringe for single intra-articular injection into the synovial
space of the joint.
RenehaVisTM LMW Sodium hyaluronate 15.4mg/0.7ml and
HMW Sodium hyaluronate 7.0mg/0.7ml For the relief of the
symptoms of osteoarthritis of the knee by providing support
and lubrication to the knee joint.

Dosage and Administration
Injection of RenehaVisTM should only be made by a Healthcare
Professional trained in the technique.
The dosage regimen is injection into the affected synovial joint space
once a week for up to three injections depending on the severity of
the degenerative change to the knee joint.
Clean the skin around the injection site with antiseptic and allow to
dry before injection is given. If joint effusion is present it should be
aspirated before injection of RenehaVisTM.
Aspiration of a small amount of synovial fluid as part of the injection
procedure to ensure the correct positioning of the needle is possible.
Before proceeding, ensure that the plunger rod is tightly screwed
into the plunger stopper.
The contents of the syringe are sterile and should be injected
using a sterile needle of an appropriate size (25 gauge needle is
recommended). The syringe is fitted with a Luer lock (6%).
Discard the syringe and needle after single use.
Uses
For the relief of pain and stiffness of the knee joint in patients with
degenerative changes to the synovial joint. The duration of effect in
patients with grade 1 to 3 medial compartment osteoarthritis has
been demonstrated to be up to twelve months.
The performance of RenehaVisTM is due to its biocompatibility
and physicochemical properties. The LMW and HMW sodium
hyaluronate contained in RenehaVisTM is a biopolymer composed of
repeating disaccharide units of N-acetylglucosamine and glucuronic
acid and though it is biosynthesised by the bacterium Streptococcus
equi it has been shown to be the same as the sodium hyaluronate
which is found in the human body. RenehaVisTM supplements the
endogenous Sodium Hyaluronate found naturally in the synovium
but which has been depleted by degenerative and traumatic
changes to the synovial joint.

Contra-indications
Patients with known sensitivity to sodium hyaluronate.
Warnings and Precautions
Do not inject RenehaVisTM if the area of the injection is infected
or where there is evidence of skin disease. RenehaVisTM pre-filled
syringe is single use. The contents of the syringe should be used for
one injection only. Any remaining sodium hyaluronate should be
discarded. If a syringe is retained for a subsequent injection there
is a risk of contamination resulting in the possible infection of the
patient and/or foreign body reaction. RenehaVisTM should not be
re-sterilised as the device performance may be compromised which
could cause serious harm to the patient’s health and safety. Sodium
hyaluronate is manufactured by fermentation of Streptococcus equi
and rigorously purified. However, the physician should consider the
immunological and potential risks that can be associated with the
injection of any biological material.